Injectable and Implantable Antiretroviral Strategies for HIV Prevention

Antiretroviral preexposure prophylaxis has huge potential for reducing the rates of new HIV infections in at risk populations. Oral and vaginal antiretroviral formulations have been evaluated in multiple Phase IIB and Phase III effectiveness trials and there is clear evidence that these products work when used. The converse is also true; antiretrovirals do not work when they are not used and unfortunately adherence is a problem for both HIV treatment and prevention. As a consequence, long-acting injectable and implantable antiretroviral formulations are being developed for the treatment and prevention of HIV infection. It is hoped they will reduce the burden of product adherence associated with the use of oral and topical products and improve clinical outcomes associated with their use. The purpose of this review is to summarize recent preclinical and clinical research in this area of HIV prevention.